Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trialResearch in context

Summary: Background: Some locally advanced (IIIA/IIIB) non-small cell lung cancers (NSCLCs) might have surgical options available. However, information regarding the effectiveness of neoadjuvant immunotherapy for potentially resectable IIIA/IIIB NSCLC is limited. The intent of this investigation wa...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Chao Sun, Xu Wang, Yinghui Xu, Guoguang Shao, Xi Chen, Yunpeng Liu, Peng Zhang, Xingyu Lin, Xiaobo Ma, Shi Qiu, Hua He, Zhiguang Yang, Kewei Ma
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Elsevier 2024-02-01
Rangatū:	EClinicalMedicine
Ngā marau:	Non-small cell lung cancer Potentially resectable Locally advanced Neoadjuvant Chemoimmunotherapy
Urunga tuihono:	http://www.sciencedirect.com/science/article/pii/S2589537024000014
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!